Cardiovascular gene therapy - Human Genome Sciences/Transgene
Latest Information Update: 26 Oct 2005
Price :
$50 *
At a glance
- Originator Human Genome Sciences; Transgene
- Developer Human Genome Sciences
- Class Gene therapies
- Mechanism of Action Connective tissue growth factor inhibitors; Gene transference; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Peripheral vascular disorders
Most Recent Events
- 26 Oct 2005 No development reported - Preclinical for Coronary artery restenosis in USA (unspecified route)
- 26 Oct 2005 No development reported - Preclinical for Peripheral vascular disorders in USA (unspecified route)
- 07 Mar 2002 Company deal information has been updated in the overview section of the profile